Boundless Bio–Leucadia: investor conference, 202306 supply service Boundless Bio presents at Jefferies 2023 Global Healthcare Conference

	Period	2023-06-08
	Partner, 1st	Boundless Bio Inc.
	Partner, 2nd	Jefferies LLC
	Group	Leucadia (Group)
	Product	Jefferies 2023 Global Healthcare Conference New York
	Product 2	cancer drug

Boundless Bio, Inc.. (6/1/23). "Press Release: Boundless Bio to Present at the 2023 Jefferies Healthcare Conference". San Diego, CA.

Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City. Presentation details are as follows:

Date: Thursday, June 8, 2023
Time: 4:00 – 4:25 PM ET
Location: New York Marriott Marquis

About Boundless Bio

Boundless Bio is a clinical stage, next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, ecDNA, to deliver transformative therapies intended to improve and extend the lives of patients with oncogene amplified cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

Contacts

James Lee, Boundless Bio
jlee@boundlessbio.com

Media
Dan Budwick, 1AB
dan@1abmedia.com